Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ViroPharma, a developer and commercializer of novel solutions, has received the European Commission's (EC) approval for centralized marketing authorization for Cinryze (C1 inhibitor [human]) for adults and adolescents suffering from hereditary angioedema (HAE).
Subscribe to our email newsletter
The EC’s approval for the drug is indicated for treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE).
International Patient Organization for C1 Inhibitor Deficiencies executive director Henrik Boysen said now, with Cinryze licensed in the EU to both prevent and treat HAE attacks, physicians and patients have another important therapeutic option to help reduce suffering.